Company: CMND
Filing Date: 2025-11-26
Form Type: F-1
Source: 0001213900-25-115501
Chunk: 48

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-26
Form: F-1
Chunk 48
---
 the United States to realize in the United States upon judgments
of courts of the United States predicated upon our civil liability and the civil liability of our directors, officers and experts under
the United States federal securities laws. There can be no assurance that U.S. investors will be able to enforce against us, members
of our Board, officers or certain experts named herein who are residents of Canada or other countries outside the United States, any judgments
in civil and commercial matters, including judgments under the federal securities laws. There can be no assurance that U.S. investors
will be able to enforce against us, members of our Board, officers or certain experts named herein who are residents of Canada or other
countries outside the United States, any judgments in civil and commercial matters, including judgments under the federal securities laws.
There is uncertainty with respect to whether a Canadian court would take jurisdiction on a matter of liability predicated solely upon
U.S. federal securities laws, and uncertainty with respect to whether a Canadian court would enforce a foreign judgment on liabilities
predicated upon the securities laws of the United States.

<div align='center'>31

WHERE YOU CAN FIND MORE INFORMATION</div>

We have filed with the SEC a registration statement
on Form F-1 under the Securities Act relating to this offering of our Common Shares. This prospectus does not contain all of the
information contained in the registration statement. The rules and regulations of the SEC allow us to omit certain information from this
prospectus that is included in the registration statement. Statements made in this prospectus concerning the contents of any contract,
agreement or other document are summaries of all material information about the documents summarized, but are not complete descriptions
of all terms of these documents. If we filed any of these documents as an exhibit to the registration statement, you may read the document
itself for a complete description of its terms.

Our SEC filings are available to the public at
the SEC’s website at http://www.sec.gov. Upon completion of this offering, we will be subject to the information reporting
requirements of the Exchange Act that are applicable to foreign private issuers, and under those requirements will file reports with the
SEC. As a foreign private issuer, we will be exempt from the rules under the Exchange Act related to the furnishing and content of proxy
statements, and our officers, directors and principal shareholders will be exempt from the reporting and short-swing profit recovery provisions
contained in Section 16 of the Exchange Act. In addition, we will not